Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Impact Therapeutics Granted CFDA Approval for China Test of PARP Inhibitor

publication date: May 3, 2017
Impact Therapeutics of Nanjing announced its IND for a PARP inhibitor, IMP4297, was approved by the CFDA. Impact believes IMP4297 has the potential to become a best-in-class drug. In February, Impact began a Australian Phase I trial of the candidate and has already treated its first patient in China as well. The company said the CFDA issued its approval only one year after the application was submitted, showing the CFDA's reforms are speeding up the regulatory process. IMP4297 is a Class 1.1 candidate that was discovered and developed in China. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital